
Nov 25 (Reuters) - Silexion Therapeutics Corp SLXN.O:
SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SIL204, NEXT-GENERATION RNA SILENCING THERAPY, AHEAD OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER
SILEXION THERAPEUTICS CORP - PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SET FOR Q2 2026